文献速递重症综合管理与镇静镇痛

促红细胞生成素类药物在ICU危重患者中的安全性与疗效:系统评价与Meta分析

Safety and efficacy of erythropoiesis-stimulating agents in critically ill patients admitted to the intensive care unit: a systematic review and meta-analysis.
PubMed 文献 · Intensive Care Med · 2019-07-11
一句话结论纳入21项RCT共5452例ICU成人患者的Meta分析显示,促红细胞生成素类药物可能降低住院死亡率(RR 0.82),严重不良事件与血栓栓塞事件无显著差异。

该系统评价与Meta分析检索OVID MEDLINE、OVID EMBASE和Cochrane对照试验中心注册库至2019年5月20日,纳入21项RCT共5452例ICU成人患者,比较促红细胞生成素类药物(ESA)组与未接受ESA组的结局。16项研究报告了住院死亡率,ESA组为12.6%(276/2187),对照组为15.4%(339/2204),RR 0.82(95%CI 0.71-0.94,P=0.006,I²=0.0%)。严重不良事件RR 1.11(95%CI 0.94-1.31,P=0.228,I²=66%),血栓栓塞事件RR 1.22(95%CI 0.95-1.58,P=0.086,I²=47%),两组相似。作者结论认为,在异质性ICU成人群体中,主要为低或不确定质量的RCT证据提示ESA治疗可能降低死亡率。

要点

  • 16项报告住院死亡率的研究中,ESA组12.6%(276/2187)vs 对照组15.4%(339/2204),RR 0.82(95%CI 0.71-0.94,P=0.006,I²=0.0%)。
  • 严重不良事件RR 1.11(95%CI 0.94-1.31,P=0.228,I²=66%),ESA组与对照组相似。
  • 血栓栓塞事件RR 1.22(95%CI 0.95-1.58,P=0.086,I²=47%),未达统计学显著。
  • 作者结论:证据主要来自低或不确定质量的RCT,提示ESA治疗可能降低死亡率。
  • 仅1项报告住院死亡率的研究为低偏倚风险。

适用人群与场景

  • 纳入标准:随机对照试验(RCT),成人患者入住ICU,报告接受ESA治疗组与未接受ESA治疗组的死亡率比较。
  • 场景:ICU收治的成人危重患者,人群异质性大。

研究设计与关键结果

  • 研究类型:系统评价与Meta分析,纳入21项RCT,共5452例参与者。
  • 主要终点住院死亡率:16项研究报告,ESA组12.6%(276/2187)vs 对照组15.4%(339/2204),RR 0.82(95%CI 0.71-0.94,P=0.006,I²=0.0%)。
  • 严重不良事件:RR 1.11(95%CI 0.94-1.31,P=0.228,I²=66%),两组相似。
  • 血栓栓塞事件:RR 1.22(95%CI 0.95-1.58,P=0.086,I²=47%),未达统计学显著。
  • 报告住院死亡率的16项研究中仅1项为低偏倚风险。

证据类型、等级与局限

  • 证据类型:随机对照试验的系统评价与Meta分析。
  • 证据质量:作者描述为主要为低或不确定质量。
  • 局限:仅1项报告住院死亡率的研究为低偏倚风险;人群异质性大;严重不良事件分析异质性I²=66%,血栓栓塞事件分析异质性I²=47%。

对床旁实践的改变

  • 作者认为,在异质性ICU成人群体中,主要基于低或不确定质量RCT的证据提示ESA治疗可能降低死亡率。
  • 严重不良事件与血栓栓塞事件在ESA组与对照组间无显著差异,但置信区间宽且存在异质性,不能排除风险增加。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

PURPOSE: Severe immune dysregulation is common in patients admitted to the intensive care unit (ICU) and is associated with adverse outcomes. Erythropoietin-stimulating agents (ESAs) have immune-modulating and anti-apoptotic effects. However, their safety and efficacy in critically ill patients remain uncertain. We evaluated whether ESAs, administered to critically unwell adult patients admitted to the ICU, reduced mortality at hospital discharge.

METHODS: The search strategy was conducted according to a predetermined protocol and included OVID MEDLINE, OVID EMBASE and The Cochrane Central Register of Controlled Trials from inception until 20 May 2019. Publications were eligible for inclusion if they were randomized controlled trials (RCTs) including adult patients admitted to an ICU, that identified and reported a group receiving ESA therapy compared to a group not receiving ESA therapy and reported mortality. There were no language restrictions.

RESULTS: The systematic review included 21 studies with 5452 participants. In-hospital mortality, reported in 16 studies of which only one was at low risk of bias, was lower in the ESA group (276 of 2187 patients, 12.6%) than the comparator group (339 out of 2204 patients, 15.4%), [relative risk (RR) 0.82, 95% CI 0.71-0.94, P = 0.006, I2 = 0.0%]. The RR of SAEs and thromboembolic events for the ESA and comparator groups were similar, RR 1.11 (95% CI 0.94-1.31, P = 0.228, I2 66%) and 1.22 (95% CI 0.95-1.58, P = 0.086, I2 47%), respectively.

CONCLUSIONS: In heterogenous populations of critically ill adults, evidence from RCTs of mainly low or unclear quality, suggests that ESA therapy may decrease mortality.

来源:Intensive Care Med,查看原文。版权归原作者所有。

参考来源

  1. Litton E, Latham P, Inman J, et al. Safety and efficacy of erythropoiesis-stimulating agents in critically ill patients admitted to the intensive care unit: a systematic review and meta-analysis. Intensive Care Med. 2019. PMID: 31297547. doi:10.1007/s00134-019-05686-y

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。